Research Grade Baminercept Alfa

Catalog No.

DHB94302

Expression system

Mammalian Cells

Species reactivity

Human

Isotype

Fusion - [LTBR (lymphotoxin beta receptor, TNFRSF3, tumor necrosis factor receptor superfamily (TNFR) member 3, TNFCR)]2 - IGHG1 Fc (Fragment constant)

Target

TNF-beta, TNFSF1, Tumor necrosis factor ligand superfamily member 1, LTA, Lymphotoxin-alpha, LT-alpha, TNFB, TNF-C, LTB, TNFC, Tumor necrosis factor C, LT-beta, Lymphotoxin-beta, Tumor necrosis factor ligand superfamily member 3, TNFSF3, Herpes virus entry mediator ligand, LIGHT, CD258, HVEM-L, HVEML, TNFSF14, Tumor necrosis factor ligand superfamily member 14, Herpesvirus entry mediator ligand

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P01374 & Q06643 & O43557

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

BG9924, TT-47, CAS: 909110-25-4

Clone ID

Baminercept Alfa

An update of targeted therapeutic options for primary Sjögren syndrome: current status and future development., PMID:34323636

Sjögren's syndrome: Old and new therapeutic targets., PMID:31831255

Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome., PMID:31749986

Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial., PMID:29604186

Efficacy and safety of biological DMARDs modulating B cells in primary Sjögren's syndrome: Systematic review and meta-analysis., PMID:28673789

Targeting non-canonical nuclear factor-κB signalling attenuates neovascularization in a novel 3D model of rheumatoid arthritis synovial angiogenesis., PMID:27864565

Identification of Novel CD4+ T Cell Subsets in the Target Tissue of Sjögren's Syndrome and Their Differential Regulation by the Lymphotoxin/LIGHT Signaling Axis., PMID:27815440

Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis., PMID:25405351

Document Download

Research Grade Baminercept Alfa.pdf